Methodologies	O
for	O
measuring	O
carcinogen	O
adducts	O
in	O
humans	O
.	O

In	O
summary	O
,	O
although	O
some	O
of	O
the	O
more	O
optimistic	O
aspirations	O
for	O
human	O
biomonitoring	O
studies	O
envisaged	O
a	O
decade	O
ago	O
have	O
not	O
been	O
realized	O
thus	O
far	O
,	O
some	O
considerable	O
advances	O
have	O
been	O
made	O
.	O

The	O
examples	O
cited	O
above	O
indicate	O
that	O
the	O
feasibility	O
of	O
biomonitoring	O
has	O
been	O
clearly	O
established	O
.	O

In	O
addition	O
,	O
they	O
demonstrate	O
the	O
need	O
for	O
preliminary	O
biomarker	O
testing	O
and	O
validation	O
through	O
transitional	O
studies	O
prior	O
to	O
their	O
field	O
application	O
.	O

In	O
the	O
next	O
decade	O
of	O
research	O
into	O
carcinogen	O
adducts	O
in	O
humans	O
,	O
continued	O
improvements	O
in	O
the	O
reproducibility	O
and	O
specificity	O
of	O
assays	O
for	O
DNA	O
adducts	O
will	O
be	O
needed	O
.	O

Perhaps	O
the	O
increasing	O
use	O
of	O
hybrid	O
methodologies	O
to	O
concentrate	O
adducts	O
followed	O
by	O
specific	O
chemical	O
analyses	O
will	O
allow	O
such	O
adducts	O
to	O
be	O
monitored	O
more	O
precisely	O
.	O

Of	O
course	O
,	O
further	O
basic	O
research	O
into	O
the	O
mechanisms	O
of	O
carcinogenesis	O
will	O
allow	O
the	O
measurement	O
of	O
specific	O
novel	O
markers	O
which	O
are	O
more	O
closely	O
tied	O
to	O
the	O
disease	O
endpoint	O
than	O
adducts	O
.	O

The	O
development	O
of	O
new	O
assays	O
for	O
determining	O
metabolic	O
phenotypes	O
and	O
genotypes	O
relevant	O
to	O
carcinogenesis	O
should	O
improve	O
our	O
estimates	O
of	O
susceptibility	O
(	O
46	O
-	O
48	O
)	O
.	O

Such	O
new	O
approaches	O
along	O
with	O
the	O
sustained	O
improvement	O
of	O
current	O
assays	O
will	O
allow	O
molecular	O
approaches	O
to	O
continue	O
to	O
enrich	O
cancer	B-Cancer
epidemiology	O
in	O
the	O
future	O
.	O

